Patents by Inventor Stephen M. Kelsey

Stephen M. Kelsey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EXTENDING TIME TO DISEASE PROGRESSION OR SURVIVAL IN CANCER PATIENTS
    Publication number: 20180236072
    Abstract: The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab.
    Type: Application
    Filed: August 31, 2017
    Publication date: August 23, 2018
    Applicant: Genentech, Inc.
    Inventors: Mika K. Derynck, Stephen M. Kelsey
  • EXTENDING TIME TO DISEASE PROGRESSION OR SURVIVAL IN CANCER PATIENTS
    Publication number: 20150273059
    Abstract: The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab.
    Type: Application
    Filed: June 16, 2015
    Publication date: October 1, 2015
    Applicant: GENENTECH, INC.
    Inventors: Mika K. Derynck, Stephen M. Kelsey
  • COMBINATION THERAPY OF HER EXPRESSING TUMORS
    Publication number: 20150086545
    Abstract: The invention relates to tumors expressing HER2 and EGFR, using HER2-dimerization inhibitors (HDIs) and EGFR inhibitors.
    Type: Application
    Filed: December 2, 2014
    Publication date: March 26, 2015
    Applicant: GENENTECH, INC.
    Inventors: Mark X Sliwkowski, Stephen M Kelsey
  • EXTENDING TIME TO DISEASE PROGRESSION OR SURVIVAL IN CANCER PATIENTS
    Publication number: 20140186347
    Abstract: The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab.
    Type: Application
    Filed: February 10, 2014
    Publication date: July 3, 2014
    Applicant: Genentech, Inc.
    Inventors: Mika K. Derynck, Stephen M. Kelsey
  • Extending time to disease progression or survival in cancer patients
    Patent number: 8691232
    Abstract: The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: April 8, 2014
    Assignee: Genentech, Inc.
    Inventors: Mika K. Derynck, Stephen M. Kelsey
  • COMBINATION THERAPY OF HER EXPRESSING TUMORS
    Publication number: 20120251530
    Abstract: The invention relates to tumors expressing HER2 and EGFR, using HER2-dimerization inhibitors (HDIs) and EGFR inhibitors.
    Type: Application
    Filed: March 6, 2012
    Publication date: October 4, 2012
    Inventors: Mark X Sliwkowski, Stephen M. Kelsey
  • THERAPY OF PLATINUM-RESISTANT CANCER
    Publication number: 20120107391
    Abstract: The present invention concerns a method for treating platinum-resistant, ovarian cancer, primary peritoneal carcinoma or fallopian tube carcinoma with the combination of a HER2 antibody that effectively inhibits HER dimerization as well as gemcitabine.
    Type: Application
    Filed: December 1, 2011
    Publication date: May 3, 2012
    Applicant: Genentech, Inc.
    Inventor: STEPHEN M. KELSEY
  • Combination therapy of her expressing tumors
    Patent number: 8163287
    Abstract: The invention relates to tumors expressing HER2 and EGFR, using HER2-dimerization inhibitors (HDIs) and EGFR inhibitors.
    Type: Grant
    Filed: July 19, 2006
    Date of Patent: April 24, 2012
    Assignee: Genentech, Inc.
    Inventors: Mark X. Sliwkowski, Stephen M. Kelsey
  • EXTENDING TIME TO DISEASE PROGRESSION OR SURVIVAL IN CANCER PATIENTS
    Publication number: 20110165157
    Abstract: The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab.
    Type: Application
    Filed: January 21, 2011
    Publication date: July 7, 2011
    Applicant: Genentech, Inc.
    Inventors: MIKA K. DERYNCK, Stephen M. Kelsey
  • EXTENDING TIME TO DISEASE PROGRESSION OR SURVIVAL IN CANCER PATIENTS
    Publication number: 20090155259
    Abstract: The present application describes extending time to disease progression or survival in a cancer patient, where the patient's cancer displays HER activation, by treating the patient with a HER dimerization inhibitor, such as pertuzumab.
    Type: Application
    Filed: November 14, 2008
    Publication date: June 18, 2009
    Applicant: Genentech, Inc.
    Inventors: Mika K. Derynck, Stephen M. Kelsey
  • Treatment with anti-ErbB2 antibodies
    Publication number: 20040013667
    Abstract: The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as anti-ErbB2 antibodies that block ligand activation of an ErbB receptor.
    Type: Application
    Filed: June 27, 2003
    Publication date: January 22, 2004
    Applicant: GENENTECH, INC.
    Inventors: Stephen M. Kelsey, Mark X. Sliwkowski